Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Transthyretin Amyloidosis Treatment Market Size And Revenue Forecast Through 2030

The market for transthyretin amyloidosis therapies has experienced robust expansion lately, with projections indicating further growth from $4.96 billion in 2025 to $5.36 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. Historical growth drivers for this market include heightened awareness of hereditary forms of the condition, broader accessibility to genetic diagnostic tools, the emergence of therapies capable of modifying disease progression, enhanced collaboration among medical specialists, and the development of patient registries for rare diseases.

The market for transthyretin amyloidosis treatments is poised for substantial expansion in the coming years, projected to reach $7.42 billion by 2030, reflecting a compound annual growth rate of 8.5%. This projected expansion over the forecast period is anticipated to be driven by several key factors, including the ongoing development of advanced next-generation therapies for ATTR, increased financial backing for both pipeline treatments and combination therapies, enhanced accessibility through specialized pharmacies, a growing need for tailored treatment selection, and sustained growth in clinical trial endeavors. Significant trends expected to shape this market during the forecast period encompass the escalating development of precisely targeted ATTR therapies, a greater uptake of gene silencing medications, a heightened emphasis on managing the multisystemic aspects of the disease, the broadening of pipeline treatment options for various ATTR variants, and improvements in patient categorization and ongoing health monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

Transthyretin Amyloidosis Treatment Market Growth Factors Supporting Long-Term Expansion

A significant driver for the transthyretin amyloidosis treatment market’s expansion is the increasing allocation of funds towards research and development initiatives. This dedication of financial capital aims to uncover novel treatment methodologies, enhance current therapeutic approaches, and deepen the scientific comprehension of various diseases. The surge in R&D funding stems from a heightened emphasis by both governmental bodies and private enterprises on addressing rare conditions, pioneering personalized medicine, and developing cutting-edge treatment modalities. Consequently, these amplified R&D expenditures hasten the identification and progression of groundbreaking therapies, thereby enhancing therapeutic alternatives and improving patient results for those afflicted with transthyretin amyloidosis. To illustrate, a report released in November 2023 by the European Federation of Pharmaceutical Industries and Associations, a trade organization headquartered in Belgium, indicated that pharmaceutical industry spending on research and development climbed to 50,000 million in 2023, a notable increase from the 47,010 million recorded in 2022. This sustained increase in investment in research and development is thus a key factor propelling the growth trajectory of the transthyretin amyloidosis treatment market.

Transthyretin Amyloidosis Treatment Market Segment Landscape And Growth Potential

The transthyretin amyloidosis treatment market covered in this report is segmented –

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN

2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Transthyretin Amyloidosis Treatment Market Industry Trends Shaping Future Revenue Growth

Within the transthyretin amyloidosis therapeutics sector, leading pharmaceutical entities are concentrating their efforts on pioneering novel and targeted interventions, including orphan medications, with the dual objectives of improving patient prognoses and broadening therapeutic availabilities. Eplontersen stands out as an orphan drug, precisely engineered for the management of transthyretin amyloidosis, frequently benefiting from expedited regulatory pathways that facilitate its progress, as exemplified in March 2023 when Ionis Pharmaceuticals, Inc., a Canadian life sciences enterprise, secured FDA approval for Eplontersen’s new drug application, an investigational orphan drug aimed at combating familial transthyretin-mediated amyloidosis that results in debilitating polyneuropathy, a potent pharmaceutical compound conceived to curb the production of transthyretin protein, thereby addressing both inherited and sporadic forms of ATTR amyloidosis.

Transthyretin Amyloidosis Treatment Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the transthyretin amyloidosis treatment market are Pfizer Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals, Prothena Corporation plc, Eidos Therapeutics Inc, BridgeBio Pharma Inc, Neurimmune AG, AstraZeneca plc, Intellia Therapeutics Inc, Novo Nordisk A/S, YolTech Therapeutics Co Ltd, Life Molecular Imaging GmbH, Attralus Inc, Regeneron Pharmaceuticals, Silence Therapeutics, Proclara Biosciences, Corino Therapeutics, SOM Biotech, Oncopeptides AB, Takeda Pharmaceutical Company Limited, Horizon Therapeutics, Roche Holding AG, SOM Innovation Biotech SA

Access The Complete Transthyretin Amyloidosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Transthyretin Amyloidosis Treatment Market Regional Analysis And Leading Geography

North Americawas the largest region in the transthyretin amyloidosis treatment market in 2025. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model